Evaluation of the analgesic efficacies of Dexketoprofen Trometamol and Dexketoprofen Trometamol + Thiocolchicoside combinations in the impacted third molar surgery: Randomised clinical trial
Abstract:BackgroundPostoperative pain is one of the most common complications. The aim of this study is to evaluate the analgesic efficacies of dexketoprofen trometamol and two different dosages of dexketoprofen trometamol + thiocolchicoside combination in the impacted third molar tooth operation.Material and MethodsThis randomized, double-blind study included 75 patients who did not have any disease. Patients were assigned to 3 groups. Group 1 received 25 mg dexketoprofen trometamol + 4 mg thiocholchicoside, Group 2 r… Show more
“…Cigerim L. and Kaplan V. conducted a randomized, double-blind clinical trial in which they assessed the efficacy of DEX and DEX in combination therapy with thiocolchicoside in two different proportional combinations in the treatment of pain after extraction of an impacted third molar [31].…”
Introduction. Dexketoprofen(DEX) belongs to nonsteroidal anti-inflammatory drugs (NSAIDs) and has analgesic, anti-inflammatory, and antipyretic properties. DEX is an enantiomer of ketoprofen (S+) and has a stronger effect than ketoprofen. It is highly effective even after the administration of small doses. The therapy with DEX does not cause serious side effects and is additionally tolerated by the body.
Aim. The review aimed to find original scientific publications on DEX in recent years and its therapeutic efficacy, safety, and tolerability.
Method. A systematic review of scientific articles published no earlier than 2015 was carried out. Materials from the PubMed, Google Scholar, and Medline Complete databases were used. The literature review was carried out in November 2021. Among the publications found, 28 scientific articles were selected for analysis.
Results and discussion. Over the recent years, there have been many publications about DEX. Articles describing new data on DEX in the treatment of pain were analyzed, compared with other drugs and mesotherapy, the latest reports of its combination with tramadol and thiocolchicoside were reviewed, and a new slow release form of DEX and new therapeutic applications of this drug were investigated. After analyzing all the studies, it was found that DEX produced similar or more effective analgesia compared to other drugs and reduced the need for emergency medications. In addition, it was noted that using DEX in combination therapy was far better than taking it alone, and was also found to be effective in raising the epileptic threshold. Mesotherapy achieved higher results in the treatment of pain symptoms compared to DEX. The side effects that appeared as a result of the use of DEX therapy were not life-threatening.
Conclusion. The results of the review confirm that DEX is a very good analgesic, which is more potent than paracetamol and diclofenac sodium while having similar effects to dexmedetomidine and lidocaine. DEX in combination with tramadol or thiocolchicoside is more effective than when the two drugs are used alone. Scientists are working on the long-acting DEX and are looking for new applications of the drug in epilepsy and oncology.
“…Cigerim L. and Kaplan V. conducted a randomized, double-blind clinical trial in which they assessed the efficacy of DEX and DEX in combination therapy with thiocolchicoside in two different proportional combinations in the treatment of pain after extraction of an impacted third molar [31].…”
Introduction. Dexketoprofen(DEX) belongs to nonsteroidal anti-inflammatory drugs (NSAIDs) and has analgesic, anti-inflammatory, and antipyretic properties. DEX is an enantiomer of ketoprofen (S+) and has a stronger effect than ketoprofen. It is highly effective even after the administration of small doses. The therapy with DEX does not cause serious side effects and is additionally tolerated by the body.
Aim. The review aimed to find original scientific publications on DEX in recent years and its therapeutic efficacy, safety, and tolerability.
Method. A systematic review of scientific articles published no earlier than 2015 was carried out. Materials from the PubMed, Google Scholar, and Medline Complete databases were used. The literature review was carried out in November 2021. Among the publications found, 28 scientific articles were selected for analysis.
Results and discussion. Over the recent years, there have been many publications about DEX. Articles describing new data on DEX in the treatment of pain were analyzed, compared with other drugs and mesotherapy, the latest reports of its combination with tramadol and thiocolchicoside were reviewed, and a new slow release form of DEX and new therapeutic applications of this drug were investigated. After analyzing all the studies, it was found that DEX produced similar or more effective analgesia compared to other drugs and reduced the need for emergency medications. In addition, it was noted that using DEX in combination therapy was far better than taking it alone, and was also found to be effective in raising the epileptic threshold. Mesotherapy achieved higher results in the treatment of pain symptoms compared to DEX. The side effects that appeared as a result of the use of DEX therapy were not life-threatening.
Conclusion. The results of the review confirm that DEX is a very good analgesic, which is more potent than paracetamol and diclofenac sodium while having similar effects to dexmedetomidine and lidocaine. DEX in combination with tramadol or thiocolchicoside is more effective than when the two drugs are used alone. Scientists are working on the long-acting DEX and are looking for new applications of the drug in epilepsy and oncology.
“…[ 6 ] Pain pathway is relayed through dorsal horn neurons in the spinal cord, which relay to the higher centers where the pain is assimilated. [ 7 ] As the inflammation progress the intestitial fluid accumulation due to transudation from injured blood vessels and obstruction of lymphatic drainage by fibrin and fibrinogen clots derived from plasma and adjacent injured vessels leads to postoperative edema. Facial edema is difficult to quantify accurately because it involves 3 dimensions of measurement with an irregular, convex surface and can manifest itself internally as well as externally.…”
Background:
Third molar surgey always needs primary intervention as it can lead to various complications and pathologies. Considering other ways for postoperative anesthesia it was infered that submucosal group which showed simple injection technique and direct surgical site administration is more beneficial. It was noticed as a patient comfort method which can be the preferred as the drug of choice over intravenous route of dexamethasone injection.
Introduction:
Impaction of third molar is a common affliction and surgical removal is the only treatment option. The post-operative sequelae following the third molar surgery are pain, edema and trismus. The use of corticosteroids is to counteract it via various routes. Still, controversy exists in the literature regarding the administration of corticosteroids over the routes and time of administration. The purpose of this study was to compare the postoperative pain, edema and trismus following third molar surgery while using preoperative intravenous and submucosal routes of dexamethasone, in terms of pain, facial swelling, and trismus.
Materials and Methods:
This study consisted of 64 patients presented with mesioangular impacted mandibular third molar for surgical removal. Preoperative measurements of edema, trismus were analyzed. Postoperative pain was estimated using visual analogue scale. Edema was assessed by the extra oral facial measurements. Trismus was measured by recording the interincisal opening in millimeters. Dexamethasone was administered intravenously or submucosally according to the choice of operating surgeon and were divided into 2 groups.
Results:
Mean and standard deviation calculated for continuous variables. Changes in parameters was analysed using t test and Mann–Whitney U test. Here, submucosal group were reported with increased pain on the second postoperative day. On seventh postoperative day mean value turns to 0.7 ± 1 for submucosal and 0.6 ± 1.2 for intravenous group. On overall observation, intravenous group expressed statistically significant (
P
< 0.01) reduction in pain compared to the submucosal group during immediate and second postoperative days.
Conclusion:
Analyzing the previous studies, and from the experience of the present one, it could be reasonably found out that administration of submucosal dexamethasone is beneficial for overall patient compliance.
“…The force of agony is diminished by increasing the dexketoprofen trometamol and dexketoprofen trometamol + 4 mg in thiocolchicoside bunches for 3 days, and in the dexketoprofen trometamol + 8 mg thiocolchicoside bunch for as long as 24 hours. Dexketroprofen + 8 mg in the thiocalcicoside bunch started to diminish torment levels contrasted and the other two gatherings, as the impact was progressively articulated in the wake of taking the subsequent portion [4]. At long last, dexactoprofen gives a pain relieving adequacy like COX-2 inhibitors when trometamol is utilized to treat intense torment, when begun early, is very much endured, and when utilized as a major aspect of a multimodal routine, Serious agony implantation [5].…”
Section: Treatment Of Migraine With Different Drugsmentioning
Migraine is a severe headache pain causing disease that is winning in excess of 4 million individuals. There causes are not surely known, yet sufferers for the most part have various sensations towards headache torment. There is no appropriate treatment for this; patients are encouraged to avoid potential risk. Different compelling medications that have demonstrated astounding outcomes in the counteractive action of headache and are mainstream today. These medications incorporate, Dexketoprofen, galcanenzuma, Erenumab, TV-48125 and Gapant (ubrozepant and rimazapant) and losmiditan (a deton). These meds have demonstrated incredible outcomes in moderating headache torment and diminishing agony days. What's more, these prescriptions can possibly treat a headache understanding with serious torment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.